Ledipasvir/sofosbuvir fixed-dose combination for treatment of hepatitis C virus genotype 4 infection

V. Nehra, E. M. Tan, S. A. Rizza, Z. Temesgen

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Hepatitis C virus (HCV) genotype 4 accounts for 8-13% of all chronic HCV infections worldwide. Patients with HCV genotype 4 have been reported to have poor treatment responses to PEGylated interferon and ribavirin regimens. Recently a single tablet, fixed-dose combination ofsofos- buvir, an RNA-directed RNA polymerase (NS5B) inhibitor, and ledipasvir, a nonstructural protein 5A (NS5A) inhibitor; has been approved for treatment of chronic HCV infection. Two studies using the fixed-dose combination in chronic HCV genotype 4 for 12 weeks reported sustained virologic response rates at 12 weeks (SVR12) of 93-95%. Data also support the use of ledipasvir/sofosbuvir in chronic HCV genotype 4 and HIV co-infection. Administered as a single once-daily oral regimeni, this ribavirin- And interferon-free regimen is well tolerated, with low potential for adverse effects and represents a significant advancement in the treatment of chronic HCV genotype 4 infection.

Original languageEnglish (US)
Pages (from-to)111-117
Number of pages7
JournalDrugs of Today
Issue number2
StatePublished - Feb 2016


  • Directed RNA polymerase (NS5B) inhibitors
  • Fixed-dose combination
  • HCV nonstructural protein 5A (NS5A) inhibitors
  • Hepatitis C virus
  • Ledipasvir/sofosbuvir
  • RNA

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Ledipasvir/sofosbuvir fixed-dose combination for treatment of hepatitis C virus genotype 4 infection'. Together they form a unique fingerprint.

Cite this